PM 01183: all 53 studies that test it

Page 1 of 1. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.

• Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung CancerNot yet recruitingNCT07640932Phase 2
• A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCRecruitingNCT07459634Phase 2
• Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPSRecruitingNCT07328425Phase 2
• Lurbinectedin With Osimertinib in Transformed Small Cell Lung CancerRecruitingNCT07153055Phase 1/2
• An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular TypingNot yet recruitingNCT07141771Phase 1/2
• Patients With High-grade Pancreatic Neuroendocrine TumorsEnrolling by invitationNCT07121478Phase 2
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerRecruitingNCT06801834Phase 3
• Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLCRecruitingNCT06497530Phase 2
• Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLCRecruitingNCT06496048Phase 3
• Lurbinectedin in FET-Fused TumorsRecruitingNCT05918640Phase 1/2
• Dose Attenuated Chemotherapy in Compromised Patients With Lung CancerRecruitingNCT05800587Phase 2
• Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing SarcomaRecruitingNCT05734066Phase 1/2
• Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian CancerRecruitingNCT05636111Phase 1
• Study of Trilaciclib and LurbinectidinRecruitingNCT05578326Phase 2
• Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung CancerRecruitingNCT05244239Phase 1
• Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic ImpairmentRecruitingNCT05101265Phase 1
• Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.RecruitingNCT04253145Phase 1/2
• Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair MutationsCompletedNCT05229588Phase 2Results posted
• Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid TumorsTerminatedNCT05126433Phase 2Results posted
• A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung CancerActive, not recruitingNCT05091567Phase 3Results posted
• Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid TumorsCompletedNCT05072106Phase 1Results posted
• Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid TumorsCompletedNCT05063318Phase 1Results posted
• Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung CancerCompletedNCT02566993Phase 3Results posted
• Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid TumorsCompletedNCT02454972Phase 2Results posted
• Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid TumorsCompletedNCT02451007Phase 2Results posted
• Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer PatientsCompletedNCT02421588Phase 3Results posted
• Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid TumorsCompletedNCT01970540Phase 1Results posted
• A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) PatientsCompletedNCT01951157Phase 2Results posted
• Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid TumorsCompletedNCT01831089Phase 1Results posted
• A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast CancerCompletedNCT01525589Phase 2Results posted
• An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course TreatmentActive, not recruitingNCT06501976Phase 2
• Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDerWithdrawnNCT06385548Phase 1/2
• Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue SarcomasWithdrawnNCT06217536Phase 1/2
• Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)Active, not recruitingNCT06088290Phase 3
• LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue SarcomaStatus unknownNCT05876715Phase 1/2
• Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline TherapyWithdrawnNCT05574504Phase 2
• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)CompletedNCT05153239Phase 3
• Lurbinectedin + Doxorubicin In LeiomyosarcomaActive, not recruitingNCT05099666Phase 1/2
• Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing SarcomaWithdrawnNCT05042934Phase 1/2
• Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine CancersActive, not recruitingNCT04802174Phase 1/2
• Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors PatientsCompletedNCT04638491Phase 1
• Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLCTerminatedNCT04610658Phase 1
• Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung CancerActive, not recruitingNCT04607954Phase 2
• Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.CompletedNCT04358237Phase 1/2
• Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.CompletedNCT03213301Phase 2
• Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid TumorsStatus unknownNCT02684318Phase 1/2
• Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid TumorsCompletedNCT02611024Phase 1/2
• Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).CompletedNCT02210364Phase 1
• Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid TumorsCompletedNCT01980667Phase 1
• Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid TumorsCompletedNCT01970553Phase 1
• Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 WeeksCompletedNCT01405391Phase 1
• Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic SyndromeCompletedNCT01314599Phase 1
• Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid TumorsCompletedNCT00877474Phase 1

← PM 01183 overview